Product Description
Mechanisms of Action: Radioactive Agent
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Corixa
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Mantle-Cell Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT01484093 | P2 |
Completed |
Mantle-Cell Lymphoma |
2023-08-11 |
2023-08-17 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/26/2025 |
News Article |
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement |
|
06/24/2025 |
News Article |
Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC) |
|
06/19/2025 |
News Article |
dGenThera and Nusano Sign Letter of Intent for Astatine‑211 Supply |
|
06/18/2025 |
News Article |
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split |